Real-world Effectiveness of PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy in First-line PDL1-high Non-squamous Lung Cancer

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Thursday 8 April

Welcome and introduction, Scientific background and context

Natasha Leighl, Princess Margaret Cancer Centre, Toronto, ON, Canada

Real world effectiveness of PD-(L)1 inhibitors alone or in combination with chemotherapy in first-line PDL1-high non-squamous lung cancer

Solange Peters, Centre Hospitalier Universitaire Vaudois – CHUV, Lausanne, Switzerland

Critical analysis and perspectives

Federico Cappuzzo, Istituto Nazionale Tumori Regina Elena, Rome, Italy

Live discussion and Q&A

Faculty and online audience (via chat feature)

Friday 9 April

Webcast of the ESMO Virtual Plenary plus additional live Discussion and Q&A with Faculty and online audience (via chat feature)

Solange Peters, Centre Hospitalier Universitaire Vaudois – CHUV, Lausanne, Switzerland 

Federico Cappuzzo, Istituto Nazionale Tumori Regina Elena, Rome, Italy 

Tony SK Mok, Prince of Wales Hospital, Hong Kong, China

Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea

Daniel Tan, National Cancer Centre Singapore, Singapore